Skip to main content
. 2017 May 22;114(23):E4641–E4647. doi: 10.1073/pnas.1703142114

Fig. 1.

Fig. 1.

Prognostic significance of EGFL7 in younger and older CN-AML patients. (A and B) The association of EGFL7 expression levels with OS and EFS of younger adult patients (age <60 y) (A) and older patients (age ≥60 y) (B). (C) OS and EFS according to EGFL7 risk group in older CN-AML patients. The favorable risk group was comprised of patients with EGFL7 low expression/high promoter methylation; the unfavorable risk group included the remaining patients (high expression/low promoter methylation, high expression/high promoter methylation, low expression/low promoter methylation). The median values of EGFL7 expression and EGFL7 promoter methylation were used as the high/low cut points.